• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TVTX

TVTX

Travere Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD45.20

+2.24 (+5.21%)

Rating:D+

Company Profile

CEO

Eric Dube

IPO Date

2012-11-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$43.31

Prev. Close

$42.96

Day Low

$43.09

Day High

$45.57

52W Low

$13.88

52W High

$48.61

Market Cap

$4.20B

Volume

1.77M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBearish

Articles

10

Avg Positive

7.5%

Avg Negative

24.0%

Avg Neutral

68.1%

News Feed

Travere Therapeutics, Inc. (TVTX) CEO Dr. Eric Dube on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·7/31/2021·↓ negative

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·7/29/2021·↑ positive

Travere Therapeutics to Report Second Quarter 2021 Financial Results

GlobeNewsWire·7/22/2021·↓ negative

Travere: Setback Presents Cautious Opportunity

Seeking Alpha·7/18/2021·↓ negative

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

Newsfile Corp·5/29/2021·↓ negative

Why Travere Therapeutics Stock Is Plummeting Today

The Motley Fool·5/26/2021·↓ negative

Travere Therapeutics' Sparsentan Program Submission Pushed to 2022; FDA Requires More Data

Benzinga·5/26/2021·↓ negative

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

GlobeNewsWire·5/25/2021·↓ negative

Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/9/2021·↓ negative

Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research·5/6/2021·↑ positive